Carlisle Companies Inc (CSL)

97.97
0.48 0.49
NYSE : Consumer Goods
Prev Close 97.49
Open 97.60
Day Low/High 97.53 / 98.26
52 Wk Low/High 92.09 / 116.40
Volume 222.50K
Avg Volume 447.00K
Exchange NYSE
Shares Outstanding 63.17M
Market Cap 6.21B
EPS 3.90
P/E Ratio 27.69
Div & Yield 1.48 (1.50%)

Latest News

CSL Behring Joins Together With Conference Attendees To Make Donation To IPOPI

CSL Behring Joins Together With Conference Attendees To Make Donation To IPOPI

Immunoglobulin Leader Donates €15,000 to International Patient Organisation to Support Primary Immunodeficiency Awareness Initiatives

Carlisle Companies Celebrates 100 Years Of Innovation & Growth

Carlisle Companies Celebrates 100 Years Of Innovation & Growth

Carlisle Companies Incorporated (NYSE:CSL) is celebrating the 100 th anniversary of its founding in September 2017.

Gabelli & Company's Aerospace & Defense Conference

Gabelli & Company's Aerospace & Defense Conference

Gabelli & Company will host the 23 rd Annual Aerospace & Defense Conference on Thursday, September 7th, 2017 in New York City.

CSL Behring To Acquire Biotech Company Calimmune And Its Proprietary Stem Cell Gene Therapy Platform

CSL Behring To Acquire Biotech Company Calimmune And Its Proprietary Stem Cell Gene Therapy Platform

- Builds on CSL Behring's promise to patients with rare and serious diseases

Gabelli & Company's Aerospace & Defense Conference

Gabelli & Company's Aerospace & Defense Conference

Gabelli & Company will host the 23 rd Annual Aerospace & Defense Conference on Thursday, September 7th, 2017 in New York City.

Gabelli & Company's Aerospace & Defense Conference

Gabelli & Company's Aerospace & Defense Conference

Gabelli & Company will host the 23 rd Annual Aerospace & Defense Conference on Thursday, September 7th, 2017 in New York City.

Carlisle Companies To Present At Jefferies Industrials Conference In NYC On August 9

Carlisle Companies To Present At Jefferies Industrials Conference In NYC On August 9

Steven J. Ford, Vice President of Investor Relations, Secretary & General Counsel of Carlisle Companies Incorporated (NYSE:CSL), will be presenting at the Jefferies 2017 Industrials Conference in New York City, NY on...

Carlisle Companies Announces 6% Increase In Dividend And The 41st Consecutive Year Of Dividend Increases

Carlisle Companies Announces 6% Increase In Dividend And The 41st Consecutive Year Of Dividend Increases

The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a 6% increase in the Company's regular quarterly dividend, to $0.

Carlisle Reports Second Quarter 2017 Results

Carlisle Reports Second Quarter 2017 Results

Carlisle Companies Incorporated (NYSE:CSL) reported record net sales of $1,071.

HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available In The United States For Patients With Hereditary Angioedema

HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available In The United States For Patients With Hereditary Angioedema

First and only subcutaneous preventive treatment option reduced HAE attacks by 95 percent (median) in treated patients

CSL Behring Receives Orphan-Drug Exclusivity For HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])

CSL Behring Receives Orphan-Drug Exclusivity For HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])

FDA grants seven-year marketing exclusivity for subcutaneous C1-INH to prevent HAE attacks

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

New Data Demonstrate Prophylactic Treatment With IDELVION® Reduces Bleed Frequency And Has Potential To Positively Impact Patients With Haemophilia B

New Data Demonstrate Prophylactic Treatment With IDELVION® Reduces Bleed Frequency And Has Potential To Positively Impact Patients With Haemophilia B

Findings presented at the International Society on Thrombosis and Haemostasis Congress 2017 show product's impact on treatment adherence, consumption and quality of life

CSL Behring Awards Researchers To Advance Immunoglobulin Therapy In Treating Neurological Disorders

CSL Behring Awards Researchers To Advance Immunoglobulin Therapy In Treating Neurological Disorders

CIDP and Autoimmune Epilepsy Researchers Granted 2017 Interlaken Leadership Awards

New Findings Show AFSTYLA® Provides Long-lasting Efficacy Without Increased Product Consumption For Prophylactic And On-Demand Treatment Of Haemophilia A

New Findings Show AFSTYLA® Provides Long-lasting Efficacy Without Increased Product Consumption For Prophylactic And On-Demand Treatment Of Haemophilia A

Results of study, which compared AFSTYLA to octocog alfa, were presented at the International Society on Thrombosis and Haemostasis Congress 2017

New Data For Two Leading Haemophilia Medicines -- AFSTYLA® And IDELVION® -- To Be Presented At The International Society On Thrombosis And Haemostasis Congress 2017

New Data For Two Leading Haemophilia Medicines -- AFSTYLA® And IDELVION® -- To Be Presented At The International Society On Thrombosis And Haemostasis Congress 2017

New findings demonstrate CSL Behring's promise to develop and deliver innovative treatments that improve patients' lives

Carlisle Companies Acquires Drexel Metals

Carlisle Companies Acquires Drexel Metals

Carlisle Companies Incorporated (NYSE:CSL) today announced the acquisition of Drexel Metals, Inc.

Carlisle Companies To Announce 2nd Quarter Results On July 25, 2017

Carlisle Companies Incorporated (NYSE:CSL) will release second quarter 2017 results on Tuesday, July 25, 2017 after the market closes.

New Innovation In The Fight Against Hemophilia Earns CSL Behring The NORD 2017 Industry Innovation Award

Driven by its promise to save lives and protect people's health, CSL Behring is honoured to be recognized by NORD, a tireless advocate for rare disease patients.

Carlisle Reports First Quarter 2017 Results

Carlisle Companies Incorporated (NYSE:CSL) reported net sales of $857.

Carlisle Companies Declares Regular Quarterly Dividend

The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a regular quarterly dividend of $0.

Therapeutic Goods Administration Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment

- AFSTYLA is the first and only single-chain recombinant factor VIII specifically designed to treat haemophilia A

Improving Access To Lifesaving Treatments For Bleeding Disorders In The Developing World

- CSL Behring Marks World Hemophilia Day by Donating IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia

Jeffrey Modell Foundation To Open The First North African Network For Primary Immunodeficiencies

CSL Behring Sponsors the First Network of its Kind on the African Continent

TheStreet Quant Rating: B (Buy)